Lonza Group said it expects sales growth to be flat in 2024, after it reported sharply lower earnings despite higher revenue for last year due to continued investments. The Swiss life-sciences ...

Lonza Group's Earnings Growth And 6.8% ROE On the face of it, Lonza Group's ROE is not much to talk about. Yet, a closer study shows that the company's ROE is similar to the industry average of 7.9%.

Lonza on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth ...

Lonza Group AG on Friday backed its financial outlook for this year as sales and earnings rose strongly in the first half of 2022 thanks to good consumer demand. Sales totalled 2.98 billion Swiss ...

Lonza Group AG, the Swiss supplier for pharma and nutrition companies, said Chief Executive Officer Pierre-Alain Ruffieux will leave at the end of the month, the third surprise CEO departure in ...

Lonza Group Ltd currently pays a - dividend of $0.47 per year for a yield of 0.68%. Lonza Group Ltd last traded ex-dividend on Apr 9, 2012 and the next ex-dividend date is unknown.

Lonza Group was founded in Switzerland in 1897 and operates in more than 35 countries worldwide. In full year 2019, sales were CHF (Swiss Francs) 5.9 billion and core EBITDA was CHF 1.6 billion.

Lonza Group (LONN.S) has extended a collaboration with a major biopharmaceutical industry client for the supply of an antibody drug conjugate (ADC) against hard-to-treat cancers, the Swiss ...

Shares of Lonza Group climbed 2.9% in Swiss trade after Moderna reported positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus. The companies intend to ...